Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

273
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
273
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

165
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
165
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

400
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
400
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

309
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
309
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.6K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends of HIV, hepatitis C virus and syphilis seroprevalence among injection and non-injection drug users in southwestern China, 2010-2017.

AIDS care·2020
Same author

Chandler-Loop surveyed blood compatibility and dynamic blood triggered degradation behavior of Zn-4Cu alloy and Zn.

Materials science & engineering. C, Materials for biological applications·2020
Same author

Knockdown of Parkinson's disease-related gene ATP13A2 reduces tumorigenesis via blocking autophagic flux in colon cancer.

Cell & bioscience·2020
Same author

Diagnostics of skin features through 3D skin mapping based on electro-controlled deposition of conducting polymers onto metal-sebum modified surfaces and their possible applications in skin treatment.

Analytica chimica acta·2020
Same author

Spongy <i>p</i>-Toluenesulfonic Acid-doped Polypyrrole with Extraordinary Rate Performance as Durable Anodes of Sodium-Ion Batteries at Different Temperatures.

Langmuir : the ACS journal of surfaces and colloids·2020
Same author

NOD1/RIP2 signalling enhances the microglia-driven inflammatory response and undergoes crosstalk with inflammatory cytokines to exacerbate brain damage following intracerebral haemorrhage in mice.

Journal of neuroinflammation·2020

Related Experiment Video

Updated: Nov 12, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.3K

Hyperphosphatemia and Cardiovascular Disease.

Chao Zhou1, Zhengyu Shi1, Nan Ouyang2

  • 1Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Frontiers in Cell and Developmental Biology
|March 22, 2021
PubMed
Summary

Elevated phosphate levels, even within normal ranges, significantly increase cardiovascular disease risk and mortality, especially in chronic kidney disease (CKD) patients. Lowering phosphate shows promise for improving cardiovascular outcomes in CKD.

Keywords:
atherosclerosiscardiac valvular calcificationcardiovascular diseasehypertensionleft ventricular hypertrophymyocardial fibrosisphosphatevascular calcification

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

360
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.2K

Related Experiment Videos

Last Updated: Nov 12, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.3K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

360
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.2K

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Elevated serum phosphate levels, even within the typical laboratory range, are strongly linked to increased cardiovascular disease (CVD) risk and mortality in both the general population and patients with chronic kidney disease (CKD).
  • Declining kidney function in CKD leads to rising phosphate levels, which contribute to hypertension, vascular and cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy, and myocardial fibrosis through various mechanisms.

Purpose of the Study:

  • To highlight phosphate as a potential therapeutic target for improving cardiovascular outcomes in CKD patients.
  • To underscore the need for further research, including large randomized clinical trials, to confirm the causal link between phosphate excess and CVD and to evaluate the efficacy of phosphate-lowering interventions.

Main Methods:

  • This study is a review of existing research and clinical observations regarding phosphate metabolism and cardiovascular health in CKD.
  • It synthesizes evidence linking hyperphosphatemia to specific cardiovascular pathologies and discusses current management strategies.

Main Results:

  • Phosphate excess is a significant risk factor for cardiovascular complications and mortality in CKD.
  • Phosphate contributes to CVD development via mechanisms including hypertension, calcification, and cardiac remodeling.

Conclusions:

  • Phosphate is a critical therapeutic target for mitigating cardiovascular risk in CKD patients.
  • Current strategies focus on dietary and pharmacological phosphate reduction.
  • Further large-scale clinical trials are essential to establish causality and therapeutic benefits of lowering serum phosphate for CVD prevention and treatment in CKD.